AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Viridian Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG002H24301
22.37▼ 0.45 (-1.97%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
22.82
Day's Range
21.92 – 22.75
52-Week Range
13.18 – 34.29
Volume
1.2M
Avg Volume
2.0M
Share Statistics
Shares Outstanding
Employees
252
Exchange
XNAS
Listed
2014-06-18
Share count as of August 3, 2026

Viridian Therapeutics, Inc. Common Stock (VRDN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Viridian Therapeutics, Inc. Common Stock (VRDN)
What is Viridian Therapeutics, Inc. Common Stock's Market Cap?
Viridian Therapeutics, Inc. Common Stock's Market Cap is $2.5B, based on as-reported figures from SEC (XBRL) filings.
What is Viridian Therapeutics, Inc. Common Stock's Price / Sales?
Viridian Therapeutics, Inc. Common Stock's Price / Sales is 35.6×, based on as-reported figures from SEC (XBRL) filings.
What is Viridian Therapeutics, Inc. Common Stock's Revenue (TTM)?
Viridian Therapeutics, Inc. Common Stock's Revenue (TTM) is $71.1M, based on as-reported figures from SEC (XBRL) filings.
What is Viridian Therapeutics, Inc. Common Stock's Net Income (TTM)?
Viridian Therapeutics, Inc. Common Stock's Net Income (TTM) is -$387.0M, based on as-reported figures from SEC (XBRL) filings.
What is Viridian Therapeutics, Inc. Common Stock's EBITDA?
Viridian Therapeutics, Inc. Common Stock's EBITDA is -$404.7M, based on as-reported figures from SEC (XBRL) filings.
What is Viridian Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Viridian Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -3.42, based on as-reported figures from SEC (XBRL) filings.
What is Viridian Therapeutics, Inc. Common Stock's EBITDA Margin?
Viridian Therapeutics, Inc. Common Stock's EBITDA Margin is -569.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · VRDNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+278.7%+95.8%+83.3%+81958.1%
Operating expenses:
Research and development
Selling, general and administrative——
Total operating expenses
% of revenue44560.6%82489.4%93091.7%156.7%
Loss from operations
% of revenue-44460.6%-82389.4%-92991.7%-56.7%
Other income (expense), net:
Interest income
Interest expense
Change in fair value of derivative liability——
Other income (expense), net
Total other income (expense), net
Net loss
% of revenue-44760.2%-74397.9%-91178.0%-49.0%
Net loss per share, basic (in dollars per share)—
Net loss per share, diluted (in dollars per share)—